Table 3.
Sustained virologic response in patients treated with Peg IFN or standard IFN according to the baseline characteristics of patients
| Characteristic | PegIFN+RBV+AMA | IFN+RBV+AMA | P | ||
| Genotype 1 | 21/82 | 26% | 11/65 | 17% | NS |
| Non 1 | 13/24 | 54% | 5/17 | 29% | NS |
| Age ≤ 40 yr | 11/23 | 48% | 2/19 | 11% | 0.017 |
| > 40 yr | 23/83 | 28% | 14/63 | 22% | NS |
| BMI ≤ 25 kg/m2 | 22/60 | 37% | 10/47 | 21% | NS |
| > 25 kg/m2 | 8/33 | 24% | 4/28 | 14% | NS |
| Stage ≤ 3 | 27/71 | 38% | 10/56 | 18% | 0.018 |
| > 3 | 6/30 | 20% | 6/26 | 23% | NS |
| Grade ≤ 10 | 28/94 | 30% | 14/73 | 19% | NS |
| > 10 | 6/9 | 67% | 2/6 | 33% | NS |
| ALT ≤ 120 UI/L | 17/64 | 27% | 5/43 | 12% | NS |
| > 120 UI/L | 15/35 | 43% | 9/31 | 29% | NS |
| HCV-RNA ≤ 2 × 106 copies/mL | 15/41 | 37% | 8/33 | 24% | NS |
| > 2 × 106 copies/mL | 6/13 | 46% | 1/15 | 7% | 0.029 |
NS: Not significant.